Fiebig HH - Search Results

1

Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.

Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, Binder M, Fiebig HH, Mertelsmann R, Trepel M. Wehr C, et al. Among authors: fiebig hh. Int J Cancer. 2012 Jul 15;131(2):E10-20. doi: 10.1002/ijc.26464. Epub 2011 Nov 19. Int J Cancer. 2012. PMID: 21953178

2

Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro.

Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R, Mertelsmann R. Licht T, et al. Among authors: fiebig hh. Int J Cancer. 1991 Oct 21;49(4):630-7. doi: 10.1002/ijc.2910490427. Int J Cancer. 1991. PMID: 1917165

3

Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays.

Dengler WA, Schulte J, Berger DP, Mertelsmann R, Fiebig HH. Dengler WA, et al. Among authors: fiebig hh. Anticancer Drugs. 1995 Aug;6(4):522-32. doi: 10.1097/00001813-199508000-00005. Anticancer Drugs. 1995. PMID: 7579556

4

Cytotoxicity of TGF alpha-PE40 and correlation to expression of epidermal growth factor receptor.

Berger DP, Herbstritt L, Hellerich U, Schulzke S, Dengler WA, Gallo M, Pastan I, Mertelsmann R, Fiebig HH. Berger DP, et al. Among authors: fiebig hh. Eur J Cancer. 1995 Nov;31A(12):2067-72. doi: 10.1016/0959-8049(95)00422-x. Eur J Cancer. 1995. PMID: 8562167

5

Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies.

Berger DP, Herbstritt L, Dengler WA, Marmé D, Mertelsmann R, Fiebig HH. Berger DP, et al. Among authors: fiebig hh. Ann Oncol. 1995 Oct;6(8):817-25. doi: 10.1093/oxfordjournals.annonc.a059322. Ann Oncol. 1995. PMID: 8589021 Free article.

6

Intra-tumoral application of a heregulin-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects.

Groner B, Wick B, Jeschke M, Fiebig HH, Dengler W, Runau T, Mihatsch M, Kahl R, Schmidt M, Wels W, Stöcklin E. Groner B, et al. Among authors: fiebig hh. Int J Cancer. 1997 Mar 17;70(6):682-7. doi: 10.1002/(sici)1097-0215(19970317)70:6<682::aid-ijc10>3.0.co;2-c. Int J Cancer. 1997. PMID: 9096650

7

Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.

Licht T, Lübbert M, Martens C, Bross KJ, Fiebig HH, Mertelsmann R, Herrmann F. Licht T, et al. Among authors: fiebig hh. Cytokines Mol Ther. 1995 Jun;1(2):123-32. Cytokines Mol Ther. 1995. PMID: 9384669

8

Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo.

Burger AM, Hartung G, Stehle G, Sinn H, Fiebig HH. Burger AM, et al. Among authors: fiebig hh. Int J Cancer. 2001 Jun 1;92(5):718-24. doi: 10.1002/1097-0215(20010601)92:5<718::aid-ijc1257>3.0.co;2-d. Int J Cancer. 2001. PMID: 11340578

9

Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models.

Burger AM, Mengs U, Schüler JB, Fiebig HH. Burger AM, et al. Among authors: fiebig hh. Anticancer Res. 2001 May-Jun;21(3B):1965-8. Anticancer Res. 2001. PMID: 11497284

10

Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro.

Burger AM, Mengs U, Schüler JB, Fiebig HH. Burger AM, et al. Among authors: fiebig hh. Arzneimittelforschung. 2001 Sep;51(9):748-57. doi: 10.1055/s-0031-1300110. Arzneimittelforschung. 2001. PMID: 11642008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

267 results

Search Page

Filters